Pro Medicus (ASX:PME) share price surges 8% on historic results

Why did investors react so positively to the Pro Medicus financial results?

| More on:
A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Pro Medicus share price is soaring 8%
  • Net profit after tax surged by 52.7%, while the company's revenue jumped by 40%
  • CEO Dr Sam Hupert lauds it as the strongest half-year revenue and profit in Pro Medicus' history

The Pro Medicus Limited (ASX: PME) share price is lifting today amid a nearly 53% boost in net profit in its half-yearly results.

The company's shares are currently trading at $50.31, an 8.59% gain.

Let's take a look at what the health imaging company reported.

Pro Medicus share price ascends amid half-yearly results

Highlights of the company's half-year (H1 FY22) results include:

  • Revenue up 40.3% to $44.33 million
  • Net profit after tax (NPAT) of $20.68 million, a 52.7% gain
  • Underlying profit before tax of $28.8 million, a 53.5% improvement
  • Cash reserves of $76.17 million, up $14.91 million
  • Fully-franked interim dividend of 10 cents per share, a 42.9% boost

What else happened in the half?

Pro Medicus experienced growth in the North American market, where revenue increased by 50%. One highlight was winning a key contract with Novant Health worth $40 million over seven years. The company also renewed a five-year contract with Allegheny Health in Pennsylvania worth $12 million.

The company's European business also achieved a 39.6% boost in revenue. Key to this was extending a German government hospital contract to a fourth site.

And finally, its Australian business saw a 7.3% gain in revenue compared to the previous corresponding period. Key to this was rolling out the Healius Ltd (ASX: HLS) contract and extending its contract with I-Med.

Pro Medicus continued its major investment in research and development in Australia and overseas.

Big ups from management

CEO Dr Sam Hupert said the result was the strongest half-year revenue and profit in Pro Medicus' history.

We thought it was a good result with all our key financial indicators heading in the right direction, not just revenue growth but also profit growth, margin expansion and retained earnings.

There were two key drivers behind the result: The first was the significant jump in transaction revenue from our US contracts which grew by 36.8%.

The second key driver was the extension of the German government contract that we announced in 2015 to a
fourth hospital which was a material sale.

What's next for Pro Medicus?

Pro Medicus is looking to further boost its presence in the United States. It is actively targeting a "growing number of opportunities in this market."

The company is confident in its future pipeline with a presence across academic, non-academic, corporate and private markets. There is a momentum shift toward cloud-based opportunities with many customers adopting a "cloud-first" strategy. Moreover, Pro Medicus sees this as a strategic advantage given its fully cloud-native offering.

What's more, the board believes there are enough cash reserves to fund the growth of the business from its internal sources. The dividend will be paid to shareholders on 25 March.

Pro Medicus share price summary

The Pro Medicus share price has climbed 10.2% in the past year. However, Pro Medicus shares are down nearly 20% year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned around 5% over the past year.

Pro Medicus has a market capitalisation of $5.2 billion, based on today's share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Business people discussing project on digital tablet.
Earnings Results

2 ASX All Ords shares surging over 10% on strong results

Investors are buying these shares in response to strong results this morning.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Earnings Results

Xero share price rockets to record high on explosive half-year growth

The tech star delivered another impressive half year results this morning.

Read more »

A man cheers after winning computer game while woman sitting next to him looks upset.
Earnings Results

2 high-flying ASX 200 gaming shares splitting ways today

Which gaming giant is winning the admiration of investors amid results?

Read more »

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Industrials Shares

This $23 billion ASX 200 stock is surging 6% while the market sinks. Here's why

This ASX 200 stock is shrugging off the wider market sell down today and racing higher. But why?

Read more »

Unsure man analysing data on laptop.
Earnings Results

ASX 200 tech stock sees red as investors punish Q3 results

Investors continue digesting the numbers.

Read more »

Female miner smiling in front of mining vehicle.
Resources Shares

Guess which ASX lithium share is racing 8% higher on record production

Investors are sending the ASX lithium share racing higher on Wednesday.

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Earnings Results

CBA shares on watch after delivering $2.5b quarterly profit

The banking giant has made a big quarterly profit. But will it be enough for the market?

Read more »

a farmer kneels on one leg and closely examines soil from his farm against a blue sky backdrop.
Earnings Results

ASX 200 consumer stock surges despite loss and dividend cut

Investors were quick to overlook the negatives.

Read more »